Gilead Sciences set an annual wholesale price of $28 500 for its once-daily single-tablet HIV-1 medication following its August 27 approval by the Food and Drug Administration. The decision might disappoint 13 Democratic representatives who had asked the company to set a more affordable price. The tablet contains a combination of 4 drugs: cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate.
In an August 1 letter to Gilead Sciences, the representatives said setting a wholesale price above $27 000 annually for the tablet would cause problems for the AIDS Drug Assistance Program (ADAP), the federally funded program that helps states purchase HIV/AIDS drugs for low-income individuals who have limited or no prescription drug coverage. ADAP is funded through the Ryan White Program.
Mitka M. New HIV Drug Pricing. JAMA. 2012;308(14):1421. doi:10.1001/jama.2012.13452